HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

4- methyl- 5- (2- (4- morpholinophenylamino)pyrimidin- 4- yl)thiazol- 2- amine

an aurora kinase inhibitor; structure in first source

Also Known As:

CYC 116; CYC-116; CYC116

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - 4-methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine: 4
  - Pyrimidines: 510
    - 4-methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine: 4
Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiazoles: 392
    - 4-methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine: 4

Experts

1.	Choi, Wahn Soo: 1 article (05/2019)
2.	Kim, Hyuk Soon: 1 article (05/2019)
3.	Kim, Hyun Woo: 1 article (05/2019)
4.	Kim, Hyung Sik: 1 article (05/2019)
5.	Kim, Su Jeong: 1 article (05/2019)
6.	Kim, Young Mi: 1 article (05/2019)
7.	Koo, Jimo: 1 article (05/2019)
8.	Lee, Dajeong: 1 article (05/2019)
9.	Lee, Min Bum: 1 article (05/2019)
10.	Min, Keun Young: 1 article (05/2019)

Related Diseases

1.	Neoplasms (Cancer) 05/01/2019 - "An Anti-Cancer Drug Candidate CYC116 Suppresses Type I Hypersensitive Immune Responses through the Inhibition of Fyn Kinase in Mast Cells." 01/04/2013 - "On the other hand, serine hydroxymethyltransferase was found to promote the tumor growth in cells resistant to CYC116 without the influence of p53. " 06/10/2010 - "Compound 18 (CYC116) is currently undergoing phase I clinical evaluation in cancer patients." 05/01/2019 - "CYC116 [4-(2-amino-4-methyl-1,3-thiazol-5-yl)-N-[4-(morpholin-4-yl)phenyl] pyrimidin-2-amine] is under development to be used as an anti-cancer drug, but the inhibitory effects of CYC116 on the activation of mast cells and related allergy diseases have not reported as of yet. "
2.	Allergic Rhinitis 05/01/2019 - "Our results suggest that CYC116 could be used as an alternative therapeutic medication for mast cell-mediated allergic disorders, such as atopic dermatitis and allergic rhinitis."
3.	Polyploidy 06/10/2010 - "The anticancer effects of lead compound 4-methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine (18; K(i) values of 8.0 and 9.2 nM for aurora A and B, respectively) were shown to emanate from cell death following mitotic failure and increased polyploidy as a consequence of cellular inhibition of aurora A and B kinases. "
4.	Multiple Myeloma 08/01/2015 - "To investigate whether CYC116 can potentiate matrine-dependent growth inhibition and apoptosis in multiple myeloma (MM) cells. " 08/01/2015 - "Matrine and CYC116 synergistically inhibit growth and induce apoptosis in multiple myeloma cells."
5.	Hypersensitivity (Allergy) 05/01/2019 - "CYC116 [4-(2-amino-4-methyl-1,3-thiazol-5-yl)-N-[4-(morpholin-4-yl)phenyl] pyrimidin-2-amine] is under development to be used as an anti-cancer drug, but the inhibitory effects of CYC116 on the activation of mast cells and related allergy diseases have not reported as of yet. "

Related Drugs and Biologics

1.	Phosphotransferases (Kinase)
2.	Glycine Hydroxymethyltransferase (Serine Hydroxymethyltransferase)
3.	Proteins (Proteins, Gene)
4.	Amines
5.	Matrines
6.	4- (4- (N- benzoylamino)anilino)- 6- methoxy- 7- (3- (1- morpholino)propoxy)quinazoline
7.	compound 18